$323 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 82 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 55.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMGN | Buy | ImmunoGen Incequities | $26,795,400 | +4552.0% | 1,420,000 | +846.7% | 8.29% | +3382.8% |
| MRUS | Sell | Merus NVequities | $15,515,084 | +26.1% | 589,255 | -11.9% | 4.80% | -5.5% |
| MORF | Buy | Morphic Holding Incequities | $14,464,875 | +643.5% | 252,309 | +388.2% | 4.47% | +457.2% |
| SDGR | Buy | Schrodinger Incequities | $14,285,556 | +154.9% | 286,169 | +34.5% | 4.42% | +91.1% |
| KRYS | Buy | Krystal Biotech Incequities | $13,963,673 | +412.8% | 118,941 | +249.7% | 4.32% | +284.3% |
| ITCI | Buy | Intra-Cellular Therapies Incequities | $12,583,140 | +85.8% | 198,723 | +58.9% | 3.89% | +39.2% |
| AKRO | Buy | Akero Therapeutics Incequities | $11,268,958 | +45.4% | 241,357 | +19.2% | 3.49% | +9.0% |
| ORIC | Buy | Oric Pharmaceuticals Incequities | $11,258,379 | +37.6% | 1,450,822 | +1.0% | 3.48% | +3.1% |
| AKRO | New | Akero Therapeutics Inccall | $11,039,820 | – | 236,500 | +100.0% | 3.42% | – |
| Buy | MoonLake Immunotherapeuticsequities | $10,200,000 | +350.9% | 200,000 | +89.1% | 3.16% | +237.8% | |
| BIIB | Buy | Biogen Idec Incequities | $7,649,362 | +143.2% | 26,854 | +137.4% | 2.37% | +82.3% |
| ETNB | Sell | 89bio Incequities | $7,513,618 | +12.6% | 396,497 | -9.5% | 2.32% | -15.6% |
| COGT | Buy | Cogent Biosciences Incequities | $7,340,800 | +17.4% | 620,000 | +7.0% | 2.27% | -12.0% |
| ACRS | Aclaris Therapeutics Inccall | $6,755,018 | +28.2% | 651,400 | 0.0% | 2.09% | -3.9% | |
| UTHR | Buy | United Therapeutics Corpequities | $6,628,902 | +59.3% | 30,029 | +61.6% | 2.05% | +19.4% |
| MGNX | Sell | MacroGenics Incequities | $6,503,861 | -33.4% | 1,215,675 | -10.7% | 2.01% | -50.1% |
| KALV | Sell | KalVista Pharmaceuticals Incequities | $6,484,572 | +14.0% | 720,508 | -0.4% | 2.01% | -14.6% |
| VCYT | Buy | Veracyte Incequities | $5,844,117 | +25.0% | 229,451 | +9.4% | 1.81% | -6.3% |
| MRTX | New | Mirati Therapeutics Inccall | $5,419,500 | – | 150,000 | +100.0% | 1.68% | – |
| BCRX | Buy | BioCryst Pharmaceuticals Incequities | $5,356,764 | +11.2% | 760,904 | +31.7% | 1.66% | -16.7% |
| TERN | Sell | Terns Pharmaceuticals Incequities | $5,247,095 | -33.6% | 599,668 | -10.2% | 1.62% | -50.3% |
| PSTX | Buy | Poseida Therapeutics Incequities | $5,184,868 | -37.4% | 2,945,948 | +9.5% | 1.60% | -53.1% |
| Sell | Nuvalent Incequities | $4,852,375 | -33.9% | 115,067 | -59.1% | 1.50% | -50.5% | |
| GILD | Buy | Gilead Sciences Incequities | $4,658,727 | -6.6% | 60,448 | +0.5% | 1.44% | -30.0% |
| VRTX | Sell | Vertex Pharmaceuticals Incequities | $4,636,414 | +11.6% | 13,175 | -0.0% | 1.43% | -16.3% |
| TELA | Buy | Tela Bio Incequities | $4,218,537 | +632.9% | 416,440 | +669.8% | 1.30% | +448.3% |
| VKTX | Sell | Viking Therapeutics Incequities | $4,191,825 | -33.7% | 258,595 | -31.9% | 1.30% | -50.3% |
| PRAX | New | Praxis Precision Medicines Incequities | $3,997,586 | – | 3,476,162 | +100.0% | 1.24% | – |
| XENE | Buy | Xenon Pharmaceuticals Incequities | $3,840,606 | +11.0% | 99,756 | +3.2% | 1.19% | -16.8% |
| MRSN | New | Mersana Therapeutics Inccall | $3,619,000 | – | 1,100,000 | +100.0% | 1.12% | – |
| OLMA | New | Olema Pharmaceuticals Incequities | $3,525,908 | – | 390,466 | +100.0% | 1.09% | – |
| SRPT | Buy | Sarepta Therapeutics Incequities | $3,419,567 | +167.6% | 29,860 | +222.1% | 1.06% | +100.8% |
| PRTA | New | Prothena Corporation PLCequities | $3,394,950 | – | 49,721 | +100.0% | 1.05% | – |
| MRTX | New | Mirati Therapeutics Incequities | $3,295,526 | – | 91,213 | +100.0% | 1.02% | – |
| MRSN | Buy | Mersana Therapeutics Incequities | $3,290,000 | +48.2% | 1,000,000 | +85.2% | 1.02% | +11.1% |
| INSM | Buy | Insmed Incequities | $3,048,190 | +24.3% | 144,464 | +0.5% | 0.94% | -6.8% |
| PHVS | Sell | Pharvaris NVequities | $3,028,000 | -32.8% | 200,000 | -64.2% | 0.94% | -49.6% |
| ANIP | New | ANI Pharmaceuticals Incequities | $2,909,027 | – | 54,041 | +100.0% | 0.90% | – |
| PHAT | Phathom Pharmaceuticals Incequities | $2,864,000 | +100.6% | 200,000 | 0.0% | 0.89% | +50.4% | |
| CERS | Buy | Cerus Corpequities | $2,849,332 | -16.8% | 1,158,265 | +0.5% | 0.88% | -37.7% |
| MIRM | Buy | Mirum Pharmaceuticals Incequities | $2,751,921 | +8.1% | 106,375 | +0.4% | 0.85% | -19.0% |
| ACRS | Sell | Aclaris Therapeutics Incequities | $2,273,405 | +27.7% | 219,229 | -0.4% | 0.70% | -4.4% |
| INCY | Buy | Incyte Corpequities | $2,123,348 | -13.4% | 34,110 | +0.5% | 0.66% | -35.1% |
| TRVI | Trevi Therapeutics Incequities | $2,117,358 | +29.2% | 885,924 | 0.0% | 0.66% | -3.2% | |
| NTLA | Buy | Intellia Therapeutics Incequities | $2,073,989 | +47.0% | 50,858 | +34.3% | 0.64% | +10.3% |
| PLRX | Buy | Pliant Therapeutics Incequities | $1,943,678 | -26.9% | 107,267 | +7.3% | 0.60% | -45.3% |
| RYTM | New | Rhythm Pharmaceuticals Incequities | $1,915,610 | – | 116,168 | +100.0% | 0.59% | – |
| CBAY | New | CymaBay Therapeutics Incequities | $1,752,000 | – | 160,000 | +100.0% | 0.54% | – |
| AMAM | New | Ambrx Biopharma Incequities | $1,646,000 | – | 100,000 | +100.0% | 0.51% | – |
| CUE | Buy | Cue Biopharma Incequities | $1,472,417 | +34.7% | 403,402 | +31.7% | 0.46% | +0.9% |
| Buy | Eliem Therapeutics Incequities | $1,383,449 | -1.8% | 494,089 | +1.7% | 0.43% | -26.5% | |
| ANNX | New | Annexon Incequities | $1,372,487 | – | 389,911 | +100.0% | 0.42% | – |
| New | Zura Bio Ltdequities | $1,312,000 | – | 160,000 | +100.0% | 0.41% | – | |
| RETA | New | Reata Pharmaceuticals Incequities | $1,274,500 | – | 12,500 | +100.0% | 0.39% | – |
| ALKS | New | Alkermes Plcequities | $1,252,000 | – | 40,000 | +100.0% | 0.39% | – |
| VYGR | New | Voyager Therapeutics Incequities | $1,145,000 | – | 100,000 | +100.0% | 0.35% | – |
| VRDN | Buy | Viridian Therapeutics Incequities | $1,070,550 | +15.7% | 45,000 | +23.7% | 0.33% | -13.4% |
| RZLT | New | Rezolute Incequities | $989,097 | – | 499,544 | +100.0% | 0.31% | – |
| KPTI | Sell | Karyopharm Therapeutics Incequities | $928,983 | -84.5% | 518,985 | -66.3% | 0.29% | -88.4% |
| ALLK | Sell | Allakos Incequities | $872,000 | -7.1% | 200,000 | -5.2% | 0.27% | -30.4% |
| BMRN | New | BioMarin Pharmaceutical Incequities | $866,800 | – | 10,000 | +100.0% | 0.27% | – |
| BBIO | Buy | Bridgebio Pharma Incequities | $860,000 | +29.7% | 50,000 | +25.0% | 0.27% | -2.9% |
| PNT | Sell | Point Biopharma Global Incequities | $848,922 | -41.2% | 93,700 | -52.8% | 0.26% | -55.9% |
| Sell | Ventyx Biosciences Incequities | $820,000 | -65.0% | 25,000 | -64.3% | 0.25% | -73.8% | |
| PTGX | Sell | Protagonist Therapeutics Incequities | $690,500 | -71.5% | 25,000 | -76.3% | 0.21% | -78.6% |
| Jasper Therapeutics Incequities | $685,000 | -24.3% | 500,000 | 0.0% | 0.21% | -43.3% | ||
| ALGS | Aligos Therapeutics Incequities | $613,562 | +11.1% | 631,887 | 0.0% | 0.19% | -16.7% | |
| New | Biohaven Ltdequities | $478,400 | – | 20,000 | +100.0% | 0.15% | – | |
| SNDX | New | Syndax Pharmaceuticals Incequities | $418,600 | – | 20,000 | +100.0% | 0.13% | – |
| CGEN | Compugen Ltdequities | $376,414 | +62.4% | 330,188 | 0.0% | 0.12% | +20.8% | |
| IMTX | Sell | Immatics Nvequities | $354,451 | -81.8% | 30,715 | -89.1% | 0.11% | -86.3% |
| CLDX | Sell | Celldex Therapeutics Incequities | $339,300 | -88.9% | 10,000 | -88.2% | 0.10% | -91.6% |
| FGEN | New | FibroGen Inccall | $271,000 | – | 100,000 | +100.0% | 0.08% | – |
| CLNN | New | Clene Incequities | $219,975 | – | 250,000 | +100.0% | 0.07% | – |
| GLUE | Monte Rosa Therapeutics Incequities | $213,419 | -12.1% | 31,156 | 0.0% | 0.07% | -34.0% | |
| Eloxx Pharmaceuticals Incequities | $210,352 | +55.0% | 54,075 | 0.0% | 0.06% | +16.1% | ||
| PIRS | New | Pieris Pharmaceuticals Incequities | $159,101 | – | 961,338 | +100.0% | 0.05% | – |
| EVGN | New | Evogene Ltdequities | $107,000 | – | 100,000 | +100.0% | 0.03% | – |
| GKOS | New | Glaukos Corpequities | $71,210 | – | 1,000 | +100.0% | 0.02% | – |
| VRAY | Sell | Viewray Incequities | $35,220 | -99.6% | 100,000 | -96.4% | 0.01% | -99.7% |
| Rocket Pharmaceuticals Incwarrants | $19,917 | +72.7% | 104,828 | 0.0% | 0.01% | +20.0% | ||
| Fresh Tracks Therapeutics Incequities | $7,013 | +6.3% | 10,000 | 0.0% | 0.00% | -33.3% | ||
| LVTX | Exit | LAVA Therapeutics NVequities | $0 | – | -140,291 | -100.0% | -0.10% | – |
| CVRX | Exit | Cvrx Incequities | $0 | – | -30,000 | -100.0% | -0.12% | – |
| ABOS | Exit | Acumen Pharmaceuticals Incequities | $0 | – | -146,922 | -100.0% | -0.25% | – |
| Exit | Astria Therapeutics Incequities | $0 | – | -93,823 | -100.0% | -0.52% | – | |
| MCRB | Exit | Seres Therapeutics Incequities | $0 | – | -232,525 | -100.0% | -0.54% | – |
| RXDX | Exit | Prometheus Biosciences Incequities | $0 | – | -13,921 | -100.0% | -0.62% | – |
| ALT | Exit | Altimmune, Inccall | $0 | – | -415,700 | -100.0% | -0.72% | – |
| MDGL | Exit | Madrigal Pharmaceuticals Incequities | $0 | – | -10,000 | -100.0% | -1.00% | – |
| CGEM | Exit | Cullinan Oncology Incequities | $0 | – | -265,032 | -100.0% | -1.12% | – |
| ALNY | Exit | Alnylam Pharmaceuticals Incequities | $0 | – | -14,043 | -100.0% | -1.16% | – |
| ETNB | Exit | 89bio, Inccall | $0 | – | -200,000 | -100.0% | -1.26% | – |
| REGN | Exit | Regeneron Pharmaceuticals Incequities | $0 | – | -5,000 | -100.0% | -1.70% | – |
| IMGN | Exit | ImmunoGen, Inccall | $0 | – | -1,128,200 | -100.0% | -1.79% | – |
| PLRX | Exit | Pliant Therapeutics, Inccall | $0 | – | -199,600 | -100.0% | -2.19% | – |
| BLU | Exit | Bellus Health Incequities | $0 | – | -1,000,000 | -100.0% | -2.97% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- SilverArc Capital, LLC #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| 13F-HR | 2022-10-28 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.